替米沙坦和卡托普利联合治疗糖尿病肾病蛋白尿

Effect of combined treatment of telmisartan plus captopril on diabetic nephropathy proteinuria

目的:观察替米沙坦和卡托普利联合治疗糖尿病肾病蛋白尿的临床疗效与安全性。方法:56例糖尿病肾病蛋白尿患者随机分为替米沙坦组、卡托普利组、联合组,治疗12周时对3组进行临床疗效评价。结果:治疗12周后,联合组患者收缩期血压(SBP)、舒张期血压(DBP)、尿蛋白排泄(UAE)和替米沙坦组、卡托普利组比较差异有统计学意义(P<0.01)。3组肾功能(BUN,Scr),空腹血糖(FBG)、糖化血红蛋白(HbAIC)、K+治疗前后各组间差异无显著性。结论:替米沙坦和卡托普利联合后治疗糖尿病肾病蛋白尿优于替米沙坦或卡托普利单一用药,且不良反应更少。

Objective To investigate the efficacy and safety of combined treatment of telmisartan plus captopril on diabetic nephropathy proteinuria. Methods 56 patients with diabetic nephropathy proteinuria were randomly divided into telmisartan group, captopril group, and combined treatment group. The clinical effects of the three groups were analyzed 12 weeks later. Results There were significant differences in systolic blood pressure, diastolic blood pressure, and urinary protein excretion between combined treatment group and telmisartan group or captopril group （P 0.01） 12 weeks after the treatment. There were no significant differences in the renal function （BUN and Scr）, fast blood glucose （FBG）, HbAIC, and K＋ before or after treatment among the three groups. Conclusion The combined treatment of telmisartan and captopril is more effective and safe than the treatment with telmisartan or captopril solo for diabetic nephropathy proteinuria.